TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness.

Project: Research

Project Details

StatusActive
Effective start/end date26/02/22 → 1/01/26

Keywords

  • Hepatology
  • Gastroenterology
  • Clinical trial